Tavares Guilherme, Kelmann Gizela, Tustumi Francisco, Tundisi Catherine Nardini, Silveira Bárbara Regina Bruço, Barbosa Bruno Maximiliano Augusto Colombo, Winther Diana Bragança, Boutros Eduarda Conte, Villar Gabriel Dos Santos, Brunocilla Giovanna, Lourenção Gustavo Rodrigues Caldas, Ferreira Jiulia Giovanna Aranha, Bernardo Wanderley Marques
Department of Evidence-Based Medicine, Centro Universitário Lusíada - Santos, SP, Brazil.
Department of Evidence-Based Medicine, Universidade de São Paulo - São Paulo, SP, Brazil.
Dement Neuropsychol. 2021 Jul-Sep;15(3):396-404. doi: 10.1590/1980-57642021dn15-030013.
Zolpidem is one of the most widely prescribed hypnotic (non-benzodiazepine) agents for sleep disorder. Recently, an increase in the demand for this drug has been observed, mainly in the elderly population.
This study aims to analyze the acute effect of zolpidem on cognitive and balance dysfunctions in the elderly population.
A study was conducted by two independent researchers in four virtual scientific information bases and included randomized controlled trials. The studies evaluated elderly patients using zolpidem. Cognitive and balance dysfunctions were analyzed.
Six articles were included. The mean age of the participants in the studies was 69 years. The following zolpidem dosages were evaluated: 5, 6.25, 10, and 12.5 mg. Comparing zolpidem and placebo, relating to the cognitive dysfunctions, there is no statistically significant difference between the groups. However, in relation to balance dysfunctions, there is a statistically significant difference between the intervention and the comparison, favoring placebo.
Zolpidem, even in usual doses (5 mg and 10 mg), has shown to increase the risk for balance dysfunctions. However, this does not occur in relation to cognitive changes.
唑吡坦是治疗睡眠障碍最常用的催眠药(非苯二氮䓬类)之一。最近,观察到对这种药物的需求有所增加,主要是在老年人群中。
本研究旨在分析唑吡坦对老年人群认知和平衡功能障碍的急性影响。
由两名独立研究人员在四个虚拟科学信息库中进行了一项研究,纳入随机对照试验。研究评估了使用唑吡坦的老年患者。分析了认知和平衡功能障碍。
纳入六篇文章。研究参与者的平均年龄为69岁。评估了以下唑吡坦剂量:5、6.25、10和12.5毫克。比较唑吡坦和安慰剂,就认知功能障碍而言,两组之间无统计学显著差异。然而,就平衡功能障碍而言,干预组与对照组之间存在统计学显著差异,支持安慰剂组。
唑吡坦即使在常用剂量(5毫克和10毫克)下,也已显示会增加平衡功能障碍的风险。然而,在认知变化方面并非如此。